Sleep-related experimental peptide · Fact sheet
DSIP
Also known as Delta sleep-inducing peptide · Emideltide
DSIP is an experimental peptide named for early sleep research. Small human studies do not establish it as an effective insomnia treatment; one controlled study found weak objective effects and no subjective sleep improvement.
What is DSIP?
Delta sleep-inducing peptide is also called emideltide. Its name describes a research history, not a proven clinical result.
Benefits & claims
Deeper sleep, fewer awakenings, and improved next-day recovery are common expectations. The distinction between a subjective experience and measured sleep improvement matters here.
What the evidence supports
- Some early reports suggested sleep effects, but later controlled findings were weak and inconsistent.
- The 16-person study did not show improved subjective sleep quality.
Research areas
- Insomnia
- Sleep efficiency
- Sleep physiology
Dosage & frequency
No established human regimenSmall, older human sleep experiments do not establish a reproducible DSIP treatment regimen. There is no FDA-approved DSIP sleep medicine.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Sleep-related study findings do not establish equivalence among injected or intranasal preparations.
Interactions & precautions
- Small sleep experiments do not establish compatibility with sedatives, sleep medicines, or other CNS-active treatments.
What is still unresolved
- Consistent efficacy, formulation, timing, and long-term safety remain unresolved.
Side effects & risks
- FDA describes peptide-quality concerns and inadequate safety information for proposed routes.
- Small historical studies cannot establish the likelihood of uncommon harms or effects of prolonged exposure.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceThe historical human literature is small. A double-blind study of 16 people with chronic insomnia did not find a major therapeutic benefit; some apparent changes could reflect differences in the placebo group.
Studies
Small matched-pairs double-blind study; weak objective effects and no subjective improvement.
Historical report with limited detail in the indexed record.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 4 sourced accounts by reported effect.
Energy: reported experiences
Deeper-feeling sleep, with inconsistent or fading effects
Comments in one discussion include descriptions of deeper sleep, feeling more rested without longer sleep, and a follow-up saying the initial benefit had faded.
Amount, frequency, route and duration could not be confirmed for this account.
These are different people with uncontrolled sleep problems and other exposures. No sleep-laboratory measurements verify deeper sleep, and the thread cannot establish tolerance or durability.
Read the DSIP discussionSleep: reported experiences
No sleep improvement despite ongoing insomnia
An author described no benefit from DSIP while continuing to struggle with sleep.
Reported use in this account
- Product
- Product described as DSIP
- Amount
- Up to 500 mcg
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Not specified clearly
Other exposures described: Magnesium L-threonate, L-theanine and retatrutide; melatonin was also tried
The replies identify retatrutide, magnesium and L-theanine as concurrent exposures. Underlying sleep problems were not clinically assessed.
Read the original accountRestful sleep without easier sleep onset
A separate commenter described deeper-feeling, more continuous sleep, while saying it did not help them fall asleep.
Reported use in this account
- Product
- Product described as DSIP
- Amount
- 400 mcg during the reported helpful experience; 100–200 mcg during other experiences
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Not specified clearly
Perceived sleep depth was not confirmed by sleep-laboratory measurements.
Read the original accountDeeper-feeling sleep, with inconsistent or fading effects
Comments in one discussion include descriptions of deeper sleep, feeling more rested without longer sleep, and a follow-up saying the initial benefit had faded.
Amount, frequency, route and duration could not be confirmed for this account.
These are different people with uncontrolled sleep problems and other exposures. No sleep-laboratory measurements verify deeper sleep, and the thread cannot establish tolerance or durability.
Read the DSIP discussionSleep felt deeper but was shorter
A commenter described shorter but much deeper-feeling sleep during DSIP exposure and gave an individual amount and evening schedule.
Reported use in this account
- Product
- Product described as DSIP
- Amount
- 150 mcg
- Frequency
- Five evenings per week
- Route
- Not specified clearly
- Duration
- Eight weeks stated by the commenter
Sleep depth and duration were not measured, and product identity was unverified. The source does not establish an administration route or clarify whether the full stated duration had already elapsed.
Read the amount-and-sleep accountNo clear change: reported experiences
No sleep improvement despite ongoing insomnia
An author described no benefit from DSIP while continuing to struggle with sleep.
Reported use in this account
- Product
- Product described as DSIP
- Amount
- Up to 500 mcg
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Not specified clearly
Other exposures described: Magnesium L-threonate, L-theanine and retatrutide; melatonin was also tried
The replies identify retatrutide, magnesium and L-theanine as concurrent exposures. Underlying sleep problems were not clinically assessed.
Read the original accountApproval status
DSIP is not an FDA-approved insomnia medicine. The cited older studies should not be presented as an active late-stage development program.
Historical studies; no FDA-approved sleep use
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Reproducible benefit for chronic insomnia
- Effects on next-day function
- Long-term safety and medication interactions
Summary
Small, inconsistent studies have not established a dependable sleep benefit.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: safety concerns for selected bulk substances
Ingredient-specific safety findings; compounding review is not drug approval.
- pubmedDSIP in chronic insomnia: a controlled study
Small matched-pairs double-blind study; weak objective effects and no subjective improvement.